Satellite symposium and exhibition exchange highlight clinicians’ high interest in MRD, MCED, and clinically evidence-based genetic testing applications.
TaipeiMay 22, 2026 /PRNewswire/ — Gene Solutions, a global innovative biotechnology company dedicated to advancing AI-driven multi-omics cancer genetic testing and precision oncology solutions, recently participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its official debut at a major oncology conference in Taiwan.
Through its satellite symposium and exhibition booth, Gene Solutions engaged in in-depth discussions with Taiwanese oncology experts on the clinical applications of multi-omics liquid biopsy in multi-cancer early detection (MCED), treatment decision-making, minimal residual disease (MRD) monitoring, and recurrence tracking. Attending physicians demonstrated a high level of familiarity with genetic testing and expressed strong interest in advanced MRD and MCED applications supported by clinical evidence.
Satellite Symposium: “Practical Applications of Multi-Omics Liquid Biopsy: Advancing Precision Oncology in Taiwan”
The symposium opened with a welcome address by Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions. She highlighted the company’s strong global track record, including over 3.2 million genetic tests completed worldwide and more than 70,000 cancer genetic analyses and ctDNA dynamic monitoring tests performed in Asia. Ida showcased Gene Solutions’ AI-driven integrated platform, which combines multi-omics data (genomics, epigenomics, fragmentomics, and transcriptomics) with clinical data to provide actionable insights throughout the cancer care journey — from SPOT-MAS for multi-cancer early detection (MCED), to K-TRACK and K-4CARE, which integrate comprehensive DNA+RNA analysis with AI-enhanced tools such as OriCUP and fusion gene detection, to integrated ctDNA-based MRD monitoring for treatment selection, resistance tracking, and tumor dynamics assessment. Ida concluded by emphasizing that the core goal of this initiative is to translate these innovations into real-world clinical value in Taiwan’s oncology practice.
Academic Agenda and Speaker Highlights
The event brought together a distinguished panel of experts to discuss the growing clinical role and trends of liquid biopsy in precision oncology, focusing on key areas such as multi-omics, artificial intelligence (AI), minimal residual disease (MRD), and multi-cancer early detection (MCED).
Dr. Aaron Tan Chia-Ken, Assistant Professor at the National Cancer Centre Singapore, delivered a presentation titled “The Value of Liquid Biopsy and Multi-Omics Across the Cancer Care Continuum.” He elaborated on the broad clinical applications of liquid biopsy — from genotyping and treatment selection in advanced disease, to circulating tumor DNA (ctDNA) monitoring for treatment response assessment, ctDNA-based minimal residual disease (MRD) evaluation in early-stage cancer, and multi-cancer early detection (MCED).
Dr. Tan emphasized that clinical technology has evolved from traditional single-driver gene testing to integrated multi-omics approaches, enabling a more comprehensive capture of tumor heterogeneity and clonal evolution. He illustrated these concepts with a real-world case of a patient with multiple primary lung cancers. His talk highlighted the increasingly important role of comprehensive multi-omics liquid biopsy in advancing precision oncology practice.
Dr. Le Son Tran, Chief Researcher and R&D Lead at Gene Solutions, introduced the scientific foundation of Gene Solutions’ AI-driven multi-omics ctDNA platform, SPOT-MAS, and its application in multi-cancer early detection (MCED). Dr. Le Son noted that current cancer screening models still have relatively limited coverage for several highly lethal cancers, resulting in a significant unmet need for scalable MCED solutions. Given that ctDNA levels released into the bloodstream in early-stage cancer are typically very low, multi-omics signal integration and AI-driven computational models are becoming key to enhancing early cancer detection capabilities.
Dr. Nai-Jung Chiang from Taipei Veterans General Hospital shared clinical case experiences of liquid biopsy in gastrointestinal cancers and colorectal cancer, illustrating the practical clinical value of integrating genomic and transcriptomic analysis with tumor-informed MRD. Dr. Chiang noted that Gene Solutions’ integrated NGS tests, such as K-TRACK and K-4CARE, provide biologically precise mutation interpretation beyond single-site detection. Additionally, Dr. Chiang emphasized the complementary value of liquid biopsy as a minimally invasive tool for long-term monitoring, recurrence tracking, and tumor heterogeneity assessment, particularly in solid tumors where repeated tissue biopsies are often difficult to obtain.
Dr. Tom Wei-Wu Chen from National Taiwan University Hospital explored the clinical integration of liquid biopsy in breast cancer and sarcoma. Dr. Chen shared research data indicating that even when imaging remains negative after curative treatment, persistent ctDNA positivity may signal a higher risk of recurrence. He also highlighted the superior sensitivity and specificity of tumor-informed MRD compared to tumor-naïve MRD testing in low disease burden scenarios. Furthermore, Dr. Chen introduced the ongoing MELODY study, a multinational randomized Phase II clinical trial evaluating pegylated liposomal doxorubicin maintenance therapy versus active surveillance in patients with advanced soft tissue sarcoma, and exploring the potential of tumor-informed ctDNA as a biomarker for risk stratification and clinical decision-making.
Professor Loong Ho-Fai from The Chinese University of Hong Kong shared perspectives on AI-driven biomarkers combined with liquid biopsy technology for precision oncology in the Asia-Pacific region. Professor Loong noted that next-generation biomarkers are evolving into AI-constructed composite biological signals, integrating radiomics, pathomics, ctDNA, methylation, and multi-omics data. He also emphasized that multi-omics platforms integrating DNA and RNA analysis are becoming important tools for in-depth tumor characterization, but face technical, biological, and computational challenges, with successful integration into routine clinical practice remaining a key issue. Professor Loong further stated that for AI-enhanced biomarkers to effectively support long-term dynamic disease monitoring and personalized treatment decisions, a more robust and convincing foundation of clinical evidence and validation is still needed.
The session concluded with an expert panel discussion moderated by Professor Loong Ho-Fai, featuring all speakers and Dr. Nguyen Duy Sinh, Oncology Medical Director and Medical Oncologist at Gene Solutions. The discussion focused on how multi-omics solutions, grounded in evidence-based medicine, can be introduced into clinical practice in Taiwan and the Asia-Pacific region, exploring future directions and clinical value.
High Physician Engagement Reflects Taiwan’s Strong Foundation for Advanced Genetic Testing
An on-site survey revealed that over 90% of attending physicians had prior experience with next-generation sequencing (NGS), indicating that Taiwan’s clinical market is well-prepared for more advanced liquid biopsy and multi-omics applications. Additionally, multi-omics technology is increasingly familiar to clinicians, and MCED is gradually being recognized as an important innovation in cancer screening and precision oncology. These results also suggest that Gene Solutions has a favorable opportunity to deepen scientific education, build clinical evidence, and foster physician collaboration in Taiwan going forward.
Among Gene Solutions’ oncology genetic testing portfolio, K-4CARE was the most closely watched product by physicians, followed by K-TRACK and other oncology diagnostic solutions. MRD was also seen as the most promising clinical entry point, with many physicians already using MRD technology or expressing strong interest in future adoption. When asked about the most important factors in introducing new diagnostic products into clinical practice, physicians ranked “clinical evidence” as the top consideration, followed by limit of detection (LOD), gene panel size, turnaround time (TAT), price, and differentiation from existing tests. These results once again underscore that evidence-centric scientific communication, robust validation data, and clinically meaningful test performance will be key foundations for advancing next-generation genetic testing solutions in Taiwan’s clinical setting.
Advancing Precision Oncology Through Integrated Genetic Analysis for Long-Term Disease Monitoring
Gene Solutions’ participation in TJCC 2026 highlights the growing clinical value and potential of AI-driven multi-omics liquid biopsy in Taiwan’s precision oncology landscape.
Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, stated: “Taiwan has a highly mature cancer care system, with clinicians possessing extensive experience in genetic testing and a willingness to embrace innovative technologies backed by clinical validation. Through our participation in TJCC 2026, we have seen clinicians actively exploring how AI-driven multi-omics liquid biopsy can enable earlier cancer detection, more precise treatment decisions, and long-term accurate ctDNA monitoring. Gene Solutions will continue to deepen collaboration with Taiwanese clinicians, hospitals, medical societies, and industry partners to bring more evidence-based, reliable, and accessible genetic testing solutions to more patients. We currently have several research programs underway, including the MELODY study initiated in partnership with Dr. Tom Wei-Wu Chen’s team at National Taiwan University Hospital.”
Dr. Tom Wei-Wu Chen also commented: “Multi-omics liquid biopsy combined with ctDNA-based MRD monitoring represents a significant advancement in precision oncology. The MELODY study we are conducting with Gene Solutions will help rigorously evaluate the value of tumor-informed MRD in sarcoma patients. In clinical scenarios requiring highly sensitive long-term monitoring, such technology has the potential to truly impact treatment decisions and ultimately improve patient outcomes.”
About Gene Solutions
Gene Solutions is a global biotechnology company headquartered in Singapore, dedicated to making advanced genomics solutions more accessible and affordable. Leveraging multi-omics, next-generation sequencing (NGS), and artificial intelligence (AI) technologies, the company offers a portfolio of products including multi-cancer early detection (SPOT-MAS) and comprehensive tumor genotyping with ctDNA monitoring (K-TRACK, K-4CARE). Since 2017, Gene Solutions has operated a CAP-accredited NGS laboratory and delivered millions of genetic tests worldwide. For more information, visit www.genesolutions.com and follow the company on LinkedIn.